TACROLIMUS | N050709 | ASTELLAS PHARMA US INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara PC FDA-2021-P-0083 · 6 docket documents Hyman, Phelps & McNamara PC filed a suitability petition regarding PROGRAF (tacrolimus), an immunosuppressant drug approved under NDA for prophylaxis of organ rejection in kidney, liver, and heart transplant patients. The petition requests guidance on the appropriateness and regulatory pathway for d | Suitability | 2021-01-26 | GrantedNo FDA response document on docket | Hyman, Phelps & McNamara PC |
Astellas Pharma US, Inc. - Citizen Petition FDA-2007-P-0111 · 11 docket documents Astellas Pharma US, Inc., the NDA holder for Prograf (tacrolimus), filed this petition under section 505(b) and (j) of the FDCA requesting that the FDA require bioequivalence studies in transplant patients for orally administered narrow therapeutic index immunosuppressants, mandate specific labeling | 505(q) | 2008-05-23 | Partially DeniedUnverified summary | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
| Code | Date | Status |
|---|---|---|
| ODE-360 | Jul 16, 2028 | Active |